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Pseudotumor cerebri (PTC) is a syndrome characterized by
raised intracranial pressure (ICP) in the absence of space-
occupying intracranial lesions on imaging, elevated CSF
opening pressure of >25 cm of water, and normal CSF com-
position.1,2 The annual incidence in the general population is
approximately 1–2 per 100,000 in North America.3,4 How-
ever, in obese women of ages 22–44 years the incidence
surges to 14.9–19.3 per 100,000.3 Clinically, as many as
90% of patients experience headaches,5 while 70% experi-
ence transient visual obscurations and pulsatile tinnitus.5,6
Binocular horizontal diplopia can also occur in the setting of
unilateral or bilateral sixth nerve palsy, a non-localizing sign
secondary to raised intracranial pressure. Papilledema seen
in these patients is usually bilateral but may be asymmetric.7
Associated vision loss can be severe in up to 25% of patients,
with blindness reported in 10% of cases.8–10Conventional treatments have been aimed at controlling
the headaches and preventing permanent vision loss from
ensuing. Given the integral relationship between obesity
and PTC, weight loss remains the most important aspect of
PTC management, with as little as 5–10% of total body
weight loss having been found to be effective in symptom
control and papilledema improvement.11 However, weight
loss is a long-term lifestyle modification and an ineffective
immediate therapy. Medical treatments that include carbonic
anhydrase inhibitors such as acetazolamide and to piramate
are frequently used. A recent multi-center, randomized dou-
ble-masked trial established that acetazolamide in conjunc-
tion with weight loss led to better and more rapid
improvement in visual fields and papilledema grade than
did diet alone. Nonetheless, with acetazolamide and to pira-
mate, patients often report paraesthesias, altered taste sen-
sation, and lethargy.12e:
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the fulminant variant of PTC.13 However, its side effect profile
includes weight gain, making this a poor treatment choice in
obese patients.
Surgical intervention is required for the subset of patients
who continue to experience intractable headaches and pro-
gressive vision loss despite medical therapy. Customarily,
optic nerve sheath fenestration (ONSF) is preferred in
patients with vision loss due to severe papilledema with rela-
tively mild or no other symptoms of increased ICP, whereas
CSF diversion procedures (e.g., ventriculoperitoneal and lum-
boperitoneal shunting) are preferred in patients with visual
loss, papilledema, and significant systemic symptoms of
increased ICP such as headache.14,15 However, these modal-
ities are not without their pitfalls. ONSF carries a risk of vision
loss, pupillary and motility dysfunction, and up to a 32% fail-
ure rate with recurrence of visual symptoms in PTC
patients.16 Shunting procedures have been associated with
shunt migration, infection, intra-cerebral hemorrhage, and
acquired Chiari malformation.17,18 Shunt failure and revision
rates have been reported as being as high as 60% for lumbo-
peritoneal shunts, and 30% for ventriculo-peritoneal shunts.19
Anatomic abnormalities of the cerebral venous sinuses
have been identified in a number of patients with PTC, and
venous sinus stenting has emerged in recent years as an alter-
ative treatment modality for these patients. We review the
current literature to assess the role of cerebral venous sinus
abnormalities in the pathogenesis of PTC and the potential
benefit of interventional treatment.Pathophysiology
The mechanisms that underlie PTC are poorly understood
and have been subject to long standing debate and specula-
tion. Prior theories have proposed increased CSF production
or decreased CSF absorption as an underlying etiology.
Recently, intracranial venous hypertension associated with
venous sinus stenosis has been implicated as a possible
mechanism for PTC.20–22 Cerebral venous sinus thrombosis
represents the extreme variant of such a phenomenon and
will not be discussed in this article, as its treatment is quite
dissimilar (anticoagulation rather than physical relief of the
obstruction). Rather, severe narrowing of one or more venous
outflow channels would increase the pressure gradient across
which CSF is resorbed at the arachnoid granulations and
cause increased ICP. Narrowing occurs most commonly at
the distal transverse sinus or transverse/sigmoid sinus junc-
tion, either unilaterally or bilaterally. Anatomic variability of
the cerebral venous sinuses is well described, and venous
sinus stenosis is distinct from these normal findings. The con-
fluences of the sinuses at the torcular herophili drain into
each transverse sinus asymmetrically. The right transverse
sinus is usually larger and drains the superior sagittal sinus,
whereas the smaller left transverse sinus usually drains the
straight sinus.22 Anatomical studies with cadaver dissections
have observed the presence of septa, especially larger septa,
which could be an etiological factor in the development of an
intrinsic pattern of venous stenosis resulting in PTC.22 The
venous sinuses are also a site for arachnoid granulations,
which are extensions of arachnoid mater and subarachnoid
space through the wall of the dural venous sinuses.22,23 Theyincrease in number with advancing age24–26 and are thought
to play a role in the resorption of CSF.27,28 They are observed
in the transverse and sigmoid sinuses28 and can cause focal
intra-luminal filling defects in 24% of CT examinations and
13% of contrast-enhanced MR studies in normal popula-
tions.29 When arachnoid granulations are enlarged, they
can obstruct either one or both transverse sinuses. It is
thought that this obstruction creates a resistance to flow,
with ensuing decreased absorption of the CSF and a concom-
itant increase in intracranial pressure.28,29 As discussed
below, relief of obstruction by a hypertrophic arachnoid
granulation has been shown to relieve PTC symptoms and
signs.
There is also evidence to suggest that transverse sinus ste-
nosis may occur as a secondary phenomenon in response to
elevated intracranial pressure. King et al.30 described the
reduction of the venous pressure in the superior sagittal
and transverse sinus, disappearance of the pressure gradient
across the transverse sinus, and resolved stenosis with CSF
drainage. De Simone et al.31 presented a case of bilateral
transverse sinus stenosis without any evidence of flow gaps.
Reversal of the stenosis was noted just 24 h after the removal
of 20 mL of CSF. Another reported patient32 with an opening
pressure of 50 cm H20 had magnetic resonance venography
(MRV) immediately before and 15 min after a lumbar punc-
ture (LP). Partial resolution of the transverse sinus narrowing
was detected with CSF drainage. A subsequent third LP
reduced the pressure to 8 cm H20 and showed complete res-
olution of the stenosis. These findings have been reproduced
by others33–35 who have reported a similar pattern of reversal
of the venous sinus stenoses either by means of lumbar punc-
ture or by CSF shunting.
Some authors36,37 have suggested the presence of a posi-
tive feedback mechanism in linking these physiological pro-
cesses. Remodeling of the transverse sinus wall in response
to sustained external compression from elevated ICP may
lead to fibrosis and formation of a fixed narrowing that can-
not reverse even with normal ICP. Changes in the bony
groove occupied by the transverse sinus have been reported
in patients with chronic ICP elevation and venous sinus steno-
sis.38 Regardless of the initial precipitating cause of the focal
stenosis, it is suggested that a cyclical mechanism of sinus
stenosis and venous hypertension further reduces CSF
absorption, raises ICP and causes worsening venous stenosis.
Irrespective of these conflicting reports, it is apparent that
a venous stenosis is somehow an important element in the
PTC progression, be it causative or resultant. Developments
and refinements in MRV imaging have now revealed that a
majority of PTC patients have transverse sinus narrowing.
Farb et al.39 utilized a high resolution, auto triggered ellip-
tic-centric-ordered (ATECO) 3-dimensional, gadolinium
enhanced MRV to detect venous stenosis. The conventional
use time-of-flight MR venography (TOF MRV), a 2-dimen-
sional system, frequently suffers from artifacts in the region
of the distal transverse sinus because of in-plane, turbulent,
and tortuous flow.40 These artifactual signal losses may be
a reason as to why the role of venous stenosis in PTC was
not identified or recognized in earlier literature. Higgins
et al.41 reanalyzed the MRVs of twenty PTC patients that
were initially interpreted as normal. Bilateral lateral sinus flow
gaps were identified in 13 of 20 patients with PTC, and in
none of 40 controls. Kumpe et al.42 reported that although
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on either CT venography or MR venography, seven were ini-
tially interpreted as normal. With the ATECO MRV technique,
Farb et al.39 have identified the presence of venous sinus ste-
noses in more than 90% of patients with PTC, compared to a
mere 6.8% in the control asymptomatic group. They con-
cluded that ATECO MRV can detect sinovenous stenosis in
PTC patients with a sensitivity and specificity of 93%. In
another recent study43, 90% of 51 PTC patients displayed
evidence of bilateral transverse sinus stenosis on MR
venography.
Zheng et al.44, reported a patient with PTC symptoms who
was found to have a large arachnoid granulation in the left
dominant transverse sinus with a hypoplastic contralateral
transverse sinus. Venous stenting across the arachnoid granu-
lation successfully reduced the pressure gradient across the
previously stenotic region. Lumbar puncture a month later
showed normal opening pressures, and at 3 months the
patient was noted to be asymptomatic. Donnet et al.45
stented the transverse sinus often in PTC patients and docu-
mented a normalization of the CSF opening pressure
3 months post procedure. This does appear to support venous
stenosis as a principal cause of raised intracranial pressure.
Endovascular procedures and characteristics
Higgins et al.21 were the first to report transverse sinus
stenting in 2002 in a PTC patient with bilateral distal trans-
verse sinus stenoses who had failed medical therapy. They
noted improved symptoms and clinical signs, including
reduction of the pressure gradient and normalization of her
CSF pressures. Since then, there has been tremendous inter-
est in this approach, and numerous other authors have pub-
lished their venous sinus stenting data with outcomes
reflecting both anatomic and symptomatic resolution of
abnormal findings.
As noted above, venous sinus stenosis may occur second-
arily in some PTC patients, and clinical and research team
members have taken a variety of approaches to investigate
the cerebral venous system before attempting any interven-
tion. In all instances, pre-procedural testing is selected to
identify the structural changes first, and if they are seen, then
further studies to establish the presence of a pressure gradi-
ent across the abnormal area are performed. Some
authors42,46 opted for patients to undergo cerebral venogra-
phy and manometry under light sedation after they showed
evidence of transverse sinus stenosis with contrast-enhanced
MRV. If a significant pressure gradient was found across the
stenotic area, then placement of the venous sinus stent was
then undertaken at the next available opportunity under gen-
eral anesthesia. Other authors47 opted to carry out the
venography under general anesthesia followed by stent
placement in the same sitting if a significant pressure gradi-
ent existed. It has been suggested that the induction of
general anesthesia causes artificially elevated venous sinus
pressure measurements due to positive pressure ventilations,
vasoactive anesthetic agents and variations in PaC02.48 How-
ever, Kumpe42 noted that pressure gradients decreased in 11
patients and increased only in 2 under general anesthesia as
compared with their corresponding readings that were taken
while awake.
Antiplatelet therapy was used routinely in the peri- and
post-procedural periods. Aspirin and clopidogrel togetherwere usually started 4–5 days prior to angiography46,49 with
intravenous heparin administered throughout the procedure
to maintain an activated clotting time of more than twice the
normal level. Dual therapy with clopidogrel and aspirin was
continued for a period of 3–6 months to allow epithelializa-
tion of the stent to occur.42,50,51 This was followed by aspirin
therapy for a year. Other studies48,52 employed warfarin in
addition to aspirin for 2 months followed by prolonged
aspirin therapy.
While most authors did measure pressure gradients across
the stenotic regions, the gradient level at which stenting was
considered is variable across institutions.42,44,46–48 In most
studies, stenting of the dural sinus was undertaken when the
pressure gradient exceeded or equaled 10 mmHg.42,45,48,50,52
Ahmed et al.46 opted to stent patients when a gradient
difference of 8 mm hg was noted and, Radvany et al.49 used
a gradient of greater than 4 mmHg. There was one study51
that did not report their measured gradients.
In most studies, unilateral venous sinus stenting was done
despite the presence of bilateral stenosis, with the apparent
dominant side or the side with the higher pressure gradient
selected. A large retrospective group analysis of 143 cases53
comprising of 15 studies showed that stents were placed in
the right transverse sinus or sigmoid sinus in 69%, the left
transverse sinus or sigmoid in 27%, or both sinuses in 4%.
Fields50 stented a patient whose dominant sinus had stenosis.
In the presence of bilateral stenosis, Radvany et al.49 opted to
stent the side with the larger pressure gradient.Clinical outcomes
In the largest cohort of 52 PTC patients46 who underwent
venous sinus stenting, all 46 with papilledema on presenta-
tion had resolution of papilledema post venous sinus stent-
ing. On presentation, 30 of the 46 patients with
papilledema had varying degrees of visual field defects rang-
ing from enlarged blind spots to severe visual field defects.
Post stenting, only 7 patients had persisting visual field loss,
of whom 4 had optic atrophy. Headache resolved in 40 and
did not change in 3 patients post procedure. Interestingly,
the headaches recurred in 6 patients and papilledema in 4
patients due to re-stenosis of the venous sinus. After re-stent
placement, the headaches and papilledema resolved in 5 and
4 of the patients respectively.
A Chinese study54 of 24 patients stented reported resolu-
tion or improvement in headaches of 16 patients, vision in 13
patients, and papilledema in 10 patients. In his initial case
series from 2002, Higgins41 reported 12 cases of venous sinus
stenting, after which 5 became asymptomatic, 2 improved
and 5 remained unchanged. Bussiere et al.47 reported 10
patients of whom 8 reported improved headache symptoms,
and 2 noted complete resolution of their headaches. Papille-
dema was resolved completely or improved in 9 patients,
with the remaining patient experiencing visual impairment
associated with optic atrophy. Donnet et al.45 reported 10
patients of which after stenting, 6 reported no headache, 2
were improved, and 2 were unchanged. All 10 patients had
documented papilledema on presentation which resolved
post stenting. However, in 2 patients, optic atrophy was
noted. Pulsatile tinnitus resolved for all 10 patients. There
was also a normalization of CSF and venous sinus pressures.
At 3 months post procedure, lumbar punctures revealed CSF
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patients. All stents were noted to be patent on follow up.
Radvany et al.49 noted that all 12 patients were found to have
headache and papilledema upon presentation. Post stenting,
the headaches resolved in 2 patients, improved in 5 patients
and persisted in the remaining 5. Tinnitus improved in 11
patients. They reported resolution of papilledema in 11
patients.
Kumpe et al.42 stented 18 patients, 16 of whom were avail-
able for fundoscopic follow up. Fifteen of these patients
showed resolution of papilledema. Visual acuity remained sta-
ble or improved in 15 patients. Two patients reported no
change in their headaches. Ten patients reported improve-
ment but persisting headache of some nature, and 2 patients
reported no change. Albuquerque et al.51, stented 18 patients,
of whom 12 patients reported improved headaches, 2 noted
unchanged symptoms and 1 noted worsening headache.
Owler et al.48 had a smaller series of 4 patients whose ste-
notic sinuses were stented. Of these 4 patients, 3 reported
resolution of their headaches, and 1 experienced occasional
headaches despite normal CSF measurements. Three
patients had resolved papilledema and 1 had no change on
fundus examination. All 3 stented patients reported by Lazz-
aro et al.55 showed resolution of papilledema, with 2 patients
reporting improved headaches. The remaining patient noted
no change in symptoms post procedure. Arac56, Ogungbo20,
Paquet57, Rajpal58 and Teleb59, each published case reports
of individual patients who underwent venous sinus stenting.
These 5 patients all were noted to have resolution of head-
aches. All but one had resolution of papilledema.
A meta-analysis60 of 19 studies with a total of 207 patients
looked at the overall clinical outcomes, although visual out-
come data were not uniformly reported in the included stud-
ies. The authors reported an improvement rate of 81% with
regard to headaches, 87% for papilledema, and 95% for pul-
satile tinnitus.
The persistence of headaches in some form, especially
amongst female patients correlates with prior reports where
as many as 48–68% of PTC patients with PTC still experience
headaches despite successful treatment.61,62 McGirt et al.61
reported as many as 48% of patients in their series experienc-
ing severe headaches despite an adequately functioning
shunt. Patients with PTC often have other causes of head-
aches, particularly those of migraine etiologies.62 Data analy-
sis of these headache symptoms and their response to
therapy in the IIHTT is currently under investigation. Overall,
we recommend headache resolution in itself should not be
used as a primary marker for successful PTC treatment.
Follow up periods varied amongst studies, with the short-
est being 2 months56, and the longest at 136 months.42 In
the largest series46 the mean pressure gradient across the ste-
nosis dropped from 19.1 mmHg to 0.6 mmHg post-stenting.
Comparable decreases have been observed in the other stud-
ies as well.42,47,50,52 Since long-term or later measurement of
the pressure gradient is unlikely to be done routinely given
its invasive nature, we can only postulate but not confirm that
the gradient does not recur in asymptomatic patients.Complications
Two patients developed in-stent thrombosis52 that
resolved with anti-thrombotic therapy. Re-stenting wasnecessary in 6 of 52 patients (12%) in the largest series.46 Five
of these 6 patients required an additional stent placement,
whereas the remaining 1 patient required 4 stents sequen-
tially. Fields et al.50 reported 2 patients requiring further
management with VP shunting and 2 other patients who
underwent bilateral stenting. Higgins et al.52 re-stented two
of patients in their series. Kumpe et al. 42 had two patients
that required retreatment. One patient needed re-stenting,
while the other required intracranial thrombolysis for throm-
bus formation that occurred downstream from the stent.
Radvany et al.49 had two patients who developed headaches
and recurrent papilledema post treatment. They were both
found to have transverse sinus stenosis proximal to the stent.
Both patients were re-stented; 1 experienced resolution of
symptoms whereas the other patient required a VP shunt
with eventual improvement in her clinical findings. There is
some evidence that oversizing the stent, a standard tech-
nique in arterial procedures, may contribute to restenosis
by causing collapse of the more distensible venous sinus wall
just proximal to the stent terminus. After reducing stent
diameter to more closely match the vessel size, we have
not had any restenosis in our stented patients.
Kumpe et al. 42 reported 1 patient with a subdural hemor-
rhage, and 2 other patients with minor complications of a uri-
nary tract infection and syncope. Ahmed et al.46 reported 1
patient with a subdural hemorrhage from a perforated intra-
cranial vein, and another patient who developed subdural,
subarachnoid and intra-cerebral bleeding. They also had 2
other patients with transient hearing loss. The three patients
in these studies who suffered intracranial hemorrhages
underwent surgical decompression. Albuquerque et al.51
reported a patient who had a retroperitoneal hematoma post
procedure, and Fields et al.50 described 1 patient with a fem-
oral pseudoaneurysm.Discussion
Venous sinus stenosis has proved to be a significant find-
ing in PTC patients, and venous stenting has emerged as
an effective treatment modality. However, it is not without
significant attendant risks. The most common complication
appears to be recurrent stenosis immediately proximal to
the stent. Other complications include stent migration, in-
stent thrombosis and, most concerning, intracranial hemor-
rhage. As Friedman63 noted in a point counter-point article,
PTC is not a life threatening disease, yet the surgical options
offered do carry fatal complications. These should be taken
into consideration when offering surgery to candidates with
milder disease processes. Weight loss and acetazolamide
should continue to be the first line therapy for PTC patients.
However, it should be noted that as many as 18–22% of PTC
patients do not respond to maximal medical therapy and
weight loss regimens.64
Failure or intolerance to medical therapy should then
prompt secondary surgical measures; optic nerve sheath fen-
estration, CSF diversion procedures and venous sinus stent-
ing are all acceptable options. All patients should have an
MRV with gadolinium contrast at initial presentation. If
venous sinus stenosis is detected on MRV, and if patients
subsequently fail medical therapy, then they should undergo
diagnostic angiography and manometry. We propose that
the manometry should be performed while the patient is
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the pressure gradient measurements. If significant venous
stenosis is noted and a pressure gradient is present, then
venous sinus stenting should be undertaken.
It has been observed that unilateral stenting of the trans-
verse sinus is sufficient to reduce pressure gradients despite
the presence of bilateral transverse sinus stenoses.49 After
venous sinus stenting, physicians must also be alert to the
recurrence of PTC symptoms and papilledema, which would
suggest re-stenosis. There are some data to suggest that
patients who had higher sagittal sinus pressures on initial
venography and higher gradient values across the stenosis
were more likely to require re-stenting.46 In this study, the
mean time to re-stenting was 20 months, with a range of
1–58 months.46 This finding further highlights the fact that
long-term data are needed to assess for stent patency, its
efficacy in preventing vision loss, and symptom control in this
patient population. Stent patency may be evaluated by
noninvasive techniques such as CT venography.
Other factors to consider in deciding upon a surgical treat-
ment method include the six-month period of anticoagula-
tion that is required post stenting. If venous sinus stenting
fails to halt vision loss, other surgical measures like CSF diver-
sion and ONSF may not be an immediate option during this
period of anti-coagulation, as an increased risk of intracranial
and retrobulbar hemorrhages respectively will exist.
The prevalence of PTC is on the rise given the increase of
obesity rates in the general population. It has been esti-
mated that the yearly costs of PTC patients have exceeded
$444 million in the United States alone.65 A recent study66
looked at the economic burden of CSF shunting procedures
versus venous sinus stenting. The authors compared 86
adults who had undergone stenting procedures for PTC to
110 children who were shunted for hydrocephalus. There
was no cost difference for the initial procedure for both
shunts and stents. However, 87% of the stents placed had
required just 1 stent procedure over the 12-year period
compared with 45% of shunts that required just one proce-
dure. The costs of shunt revisions and treatment related to
shunt infections made the shunting procedure approxi-
mately five times more costly overall. This is likely an impor-
tant consideration in the current economic environment of
medical practice.Conclusion
Since the recognition of venous sinus stenosis in PTC
patients, it has become evident that there is a role for
venous sinus stenting in the management of these patients.
Results of multiple series have shown good resolution of
papilledema and symptomatic control that is comparable
to other treatment modalities. All patients that have failed
medical therapy PTC should undergo contrast-enhanced
MRV or CTV to confirm the presence or persistence of
any venous sinus stenosis that may be contributory to the
high ICP. Venous sinus stenting then should be considered
if the measured pressure gradient across the stenosis is
significant.Conflict of interest
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